Artificial intelligence firm Anthropic PBC is stepping further into the scientific research space with the rollout of Claude Science, a new software platform intended to help researchers tackle labour-intensive aspects of their work. Launching on June 30, the tool represents the company's latest effort to position itself as an essential partner for professional sectors beyond software development, reflecting a broader industry shift toward justifying premium valuations by demonstrating real-world utility across multiple domains.
Claude Science operates as an integrated research assistant that can handle numerous tasks across biology and chemistry disciplines. Among its capabilities are functions such as protein structure prediction, a traditionally demanding process that consumes substantial researcher time. Rather than requiring scientists to toggle between disparate platforms and databases, the system consolidates access to more than 60 scientific databases into a unified interface. This architectural approach addresses a persistent friction point in academic and commercial research—the fragmentation of data sources that forces researchers to repeatedly query different platforms, cross-reference information, and manually synthesise findings into actionable insights.
The platform prioritises accessibility through natural language processing, enabling scientists to pose questions in plain conversational English rather than requiring specialised query syntax or programming knowledge. For researchers whose expertise lies in chemistry or biology rather than computational science, this reduces barriers to entry and accelerates the research process. The system handles multistep workflows that would traditionally demand either manual effort or custom programming, automating sequences of related tasks that constitute significant portions of scientific workdays. Anthropic is initially offering Claude Science as a beta product exclusively to its existing paid subscribers, a common strategy for enterprise software rollouts that allows the company to gather feedback from engaged users before broader market release.
Beyond tool release, Anthropic disclosed that it has commenced internal preclinical drug discovery operations—a significant expansion into pharmaceutical development rather than remaining purely a software vendor. The company plans to focus deliberately on therapeutic targets that established pharmaceutical and biotech corporations might overlook or consider unprofitable. This positioning could prove strategically important in regions like Southeast Asia, where research into tropical diseases, poverty-associated conditions, and underserved populations has historically received limited commercial attention from Western pharmaceutical giants. Eric Kauderer-Abrams, heading Anthropic's life sciences division, explained that the company intends to pursue research domains outside the traditional profit-maximisation focus of established industry players.
Anthropics ambitions must be contextualised within intense competition between leading AI companies to expand beyond software and demonstrate transformative applications. OpenAI, Anthropics primary rival, has similarly invested heavily in tools targeting healthcare, finance, and legal services. Anthropic itself, valued at US$965 billion (RM3.94 trillion), is reportedly preparing for an initial public offering potentially occurring this autumn. These valuations depend substantially on investor conviction that AI will generate substantial revenue across multiple sectors—a thesis the company must continually validate through concrete product launches and partnership announcements.
The event announcing Claude Science gathered influential figures from both AI and pharmaceutical sectors. Anthropic CEO Dario Amodei delivered remarks alongside Vas Narasimhan, chief executive of pharmaceutical multinational Novartis AG and an Anthropic board member, with Bristol-Myers Squibb CEO Chris Boerner also participating. This high-profile attendance underscores the announcement's significance within industry circles and signals pharmaceutical leadership's willingness to partner with or endorse AI-driven research acceleration. Amodei articulated an intention to demonstrate concrete successes in applying AI to drug target identification within the coming year, acknowledging that the industry requires tangible evidence rather than continued speculative claims about AIs potential.
Narasimhan's remarks proved particularly noteworthy, emphasising that companies making ambitious AI proclamations must now deliver measurable patient benefits and appropriate regulatory frameworks. His warning that crisis situations have historically precipitated regulation—rather than proactive governance—reflects growing concern that AI development may be outpacing prudent oversight structures. For Southeast Asian regulators and health authorities contemplating how to engage with advanced AI in research and drug discovery, Narasimhan's implicit suggestion that coordinated international regulation remains preferable to reactive crisis management warrants consideration. Regional policymakers may benefit from participating in global standard-setting discussions rather than awaiting externally imposed requirements.
Claude Science utilises Anthropic's existing Claude models, including the Opus 4.8 version released in May. A critical design feature involves transparency mechanisms allowing scientists to verify information accuracy and trace the models reasoning. When generating images, the system documents its methodology and parameters, enabling scientists to assess reliability and understand potential limitations. This transparency orientation differentiates Anthropic's approach from some competitors and addresses legitimate scientific concerns about algorithmic black boxes. Reproducibility and traceability constitute core values within research communities, and embedding these principles into AI tools may facilitate broader academic adoption.
The Claude Science launch arrives amid ongoing tension between AI advancement and national security considerations. Just days earlier, Anthropic had disabled access to its most advanced models—Fable 5 and Mythos 5—in response to Trump administration orders restricting technology access for foreign nationals. Subsequently, on June 26, Anthropic secured renewed approval to restore partial Mythos 5 access following assurances addressing national security concerns. No corresponding announcement has clarified Fable 5 status, suggesting continued restrictions on the most powerful capabilities. This regulatory environment demonstrates how geopolitical considerations increasingly shape AI deployment and how companies operating across jurisdictions must navigate divergent policy frameworks.
For Malaysian and broader Southeast Asian stakeholders, Claude Sciences emergence carries multiple implications. The platform could accelerate research capacity at regional universities and biotech companies lacking access to comprehensive scientific databases, potentially democratising research previously concentrated in resource-rich nations. Simultaneously, the tools reliance on Anthropics cloud infrastructure and regulatory compliance with US government orders introduces dependencies and potential restrictions that regional actors should contemplate strategically. As pharmaceutical development increasingly incorporates AI, policymakers should consider how to attract such innovation while maintaining appropriate oversight of both AI systems and drug discovery processes operating within their jurisdictions.
The convergence of AI capability expansion, pharmaceutical industry engagement, and regulatory pressure creates a pivotal moment for research infrastructure evolution. Anthropic positions Claude Science as an enabler of scientific acceleration, yet the underlying business model, geopolitical constraints, and transparency mechanisms warrant careful evaluation. For research institutions and companies across Southeast Asia considering integration into platforms like Claude Science, understanding both the technological opportunities and institutional implications—including dependency on US-based corporations subject to US regulatory frameworks—should inform adoption decisions and long-term research strategy.
